Cargando…

1662. Pushing the Dose: Miltefosine Treatment for a Supersized American with Cutaneous Leishmaniasis

BACKGROUND: Miltefosine (Profounda, FL) is an oral alkylphospholipid drug which is approved by the Food and Drug Administration for the treatment of some species of New World cutaneous leishmaniasis. The maximal daily recommended dosage is 50 mg t.i.d for 28 days; yet there is some evidence that dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aronson, Naomi E, Roseboom, Ignace, Digby, Michael, Bravos, Christina, Selig, Daniel, Farmer, Aaron, AM van Thiel, Pieter-Paul, Dorlo, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809767/ http://dx.doi.org/10.1093/ofid/ofz360.1526

Ejemplares similares

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
por: Palić, Semra, et al.
Publicado: (2019)

No evidence for cardiotoxicity of miltefosine()
por: Dorlo, Thomas P.C.
Publicado: (2022)

Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis()()
por: Barroso, Daniel Holanda, et al.
Publicado: (2021)

Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia
por: Ostyn, Bart, et al.
Publicado: (2014)

Miltefosine for the treatment of cutaneous leishmaniasis—A pilot study from Ethiopia
por: van Henten, Saskia, et al.
Publicado: (2021)

Supersized lipid droplets
por: Leslie, Mitch
Publicado: (2008)

Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients
por: OLLECH, Ayelet, et al.
Publicado: (2020)

Resolution of Cutaneous Old World and New World Leishmaniasis after Oral Miltefosine Treatment
por: Tappe, Dennis, et al.
Publicado: (2010)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial
por: Machado, Paulo R., et al.
Publicado: (2010)

Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature
por: Mosimann, Vincent, et al.
Publicado: (2016)

Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis
por: Iranpour, Sohrab, et al.
Publicado: (2019)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan
por: Tahir, Moizza, et al.
Publicado: (2019)

The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial
por: Tayyebi, Masoumeh, et al.
Publicado: (2021)

Community-based treatment of cutaneous leishmaniasis using cryotherapy and miltefosine in Southwest Ethiopia: the way forward?
por: van Henten, Saskia, et al.
Publicado: (2023)

The doctor's tale 1662–1975. Reigate and Redhill
Publicado: (1978)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis
por: Peixoto, Fábio, et al.
Publicado: (2020)

Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis
por: Koley, Sankha, et al.
Publicado: (2013)

Mouse chromosomes get supersized but find their limits
por: Truong, David M
Publicado: (2022)

In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis
por: Coelho, Adriano C., et al.
Publicado: (2014)

Amendment to the Draft Minutes (CERN/CC/1662/Draft)
Publicado: (1987)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
por: Ferreira, Carolina, et al.
Publicado: (2020)

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection
por: Kip, A. E., et al.
Publicado: (2016)

Is Supersize More than Just Too Much Food?
por: Birnbaum, Linda S.
Publicado: (2012)

Supersized Ribosomal RNA Expansion Segments in Asgard Archaea
por: Penev, Petar I, et al.
Publicado: (2020)

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study
por: Castro, Maria del Mar, et al.
Publicado: (2017)

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
por: Sundar, Shyam, et al.
Publicado: (2007)

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
por: Kassam, K., et al.
Publicado: (2013)

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
por: Patra, Pradyumna, et al.
Publicado: (2012)

Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2015)

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
por: Srivastava, Saumya, et al.
Publicado: (2017)

Complex cutaneous infection by Leishmania mexicana treated with miltefosine
por: Sadowsky, Rachel L., et al.
Publicado: (2022)

In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up
por: Coelho, Adriano C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nble7lmhgv2k9bdfguc18jfols